Patricia A. Martin
Director · AN2 Therapeutics, Inc.
IndividualSelling only
- 2024
- Oct 13, 2026
- 14
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Patricia A. Martin files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Christopher Mirabelli - $2.17M in CYPH purchases and sales in the last 12 months
- Douglas E. Onsi - $2.12M in CYPH purchases and sales in the last 12 months
- James H. Cavanaugh - $822K in CYPH purchases and sales in the last 12 months
- Khing Djien Oei - $662K in CYPH purchases and sales in the last 12 months
- Robin Shane Readnour - $317K in ANTX purchases and sales in the last 12 months
- Joshua M. Eizen - $53K in ANTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Patricia A. Martin?
Patricia A. Martin is a corporate insider, tracked as Director of AN2 Therapeutics, Inc. (ANTX). InsiderAlpha holds 14 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Patricia A. Martin submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Patricia A. Martin been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($193K) across all tracked filings.
